Logo
x

Search

Subscribe Now

1L

AstraZeneca Reports Results of Imfinzi in P-III TOPAZ-1 Trial as 1L Treatment for Advanced Biliary Tract Cancer

AstraZeneca Reports Results of Imfinzi in P-III TOPAZ-1 Trial as 1L Treatment for Advanced Biliary Tract Cancer

  • October 26, 2021
Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer

Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer

  • August 24, 2021
ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelio...

  • May 28, 2021
Eli Lilly and Innovent Report the US FDA's Acceptance of Sintilimab + Chemotherapy's BLA for 1L Treatment for Non-Squamous NSCLC

Eli Lilly and Innovent Report the US FDA's Acceptance of Sintilimab + Chemotherapy's BLA for 1L Treatment for Non-Squamous NSCLC

  • May 18, 2021
Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

  • March 31, 2021
Henlius Reports First Patient Dosing in P-II/III Study of HLX10 + HLX04 (biosimilar- bevacizumab) for 1L mCRC

Henlius Reports First Patient Dosing in P-II/III Study of HLX10 + HLX04 (biosimilar- bevacizumab) for 1L mCRC

  • March 11, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.